Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02508194 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy of MEDI7510 in Older Adults
A Phase 2 study, sponsored by MedImmune.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1,900
- Enrollment target
NCT02508194 is a Phase 2 study that was terminated before completion, run by MedImmune. The registered enrollment target is 1,900 participants.
The verdict
NCT02508194, a Phase 2 study, was terminated before completion, sponsored by MedImmune.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1,900 participants
- Enrollment target
Study Summary
This study will be the first assessment of the efficacy of MEDI7510 for the prevention of respiratory syncytial virus (RSV) disease. It will also provide estimates of vaccine efficacy and of endpoint incidence in the placebo arm. It will also assess the safety and immunogenicity of concurrent dosing of MEDI7510 and IIV to expand on the observations made in the Phase 1b study of MEDI7510. It will also expand the safety database of participants dosed with MEDI7510. The study will also assess the immune response to MEDI7510 in Season 1 and Season 2.
Interventions
- OTHER Placebo
- BIOLOGICAL MEDI7510
- BIOLOGICAL IIV
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,900 participants |
| Start Date | 2015-09-29 |
| Est. Completion | 2016-11-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02508194
The ClinicalTrials.gov registry entry for NCT02508194 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1,900 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02508194 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02508194 about?
NCT02508194 is a clinical study titled "A Study to Evaluate the Efficacy of MEDI7510 in Older Adults". This study will be the first assessment of the efficacy of MEDI7510 for the prevention of respiratory syncytial virus (RSV) disease. It will also provide estimates of vaccine efficacy and of endpoint incidence in the placebo arm. It will also assess the safety and immunogenicity of concurrent dosing...
What is the current status of trial NCT02508194?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1,900 participants. The study started on 2015-09-29. Estimated completion is 2016-11-07.
What interventions are being tested in trial NCT02508194?
The interventions under investigation include: Placebo (OTHER), MEDI7510 (BIOLOGICAL), IIV (BIOLOGICAL).
Who is sponsoring clinical trial NCT02508194?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.